BIOLOG-ID
31.8.2021 11:53:07 CEST | Business Wire | Press release
After a public consultation, biolog-id, a global service provider of connected healthcare solutions, through its local partner ATC, has been awarded by the Ministry of Health to deploy Biolog Transfusion Solution in Kuwait Central Blood Bank (KCBB), the national blood bank operator.
Over the years, KCBB has reached a very high scientific level and has acquired a well-deserved reputation for the quality of its blood supply chain. In the Middle East region, this institution is recognized as a leading institution for the quality of its blood supply processes and as an early adopter of leading-edge innovation. On the international stage, the KCBB has also been a pioneer in the AABB (American Association of Blood Banks) accreditation and is for long a member and significant contributor to the ISBT’s (International Society of Blood Transfusion) recommendations.
While the COVID-19 pandemic has challenged the transfusion supply chain, KCBB has chosen to adopt the cutting-edge technology Biolog Transfusion Solution to better drive its operations. Based on RFID, this modular solution combines tags, equipment, and software to offer accurate visibility on blood products throughout the transfusion chain. Designed for healthcare professionals, the solution will support KCBB to enhance GMPs and safety for all processed blood units (Red Blood Cells, Platelets & Plasma).
“We are very honored that KCBB relies on our technology to optimize its processes and its blood distribution tracking”, states Philippe Jacquet, Executive Director of Sales EMEA/LATAM at biolog-id. “This major achievement has been facilitated by our partner in Kuwait, Advanced Technology Company (ATC), who has been instrumental in the management of this project and who will coordinate the implementation of our solution”.
“ATC is very pleased and honored to have been awarded for this project, which will be the first implementation of the state-of-the-art Biolog Transfusion Solution at the prestigious Kuwait Central Blood Bank and its branches. This implementation will definitively be a millstone in the midst of continuous improvement of blood supply safety and blood processing in Kuwait” said M. Mahmoud Chehime, Director – Specialty Diagnostics & LS at ATC.
Biolog Transfusion Solution will be deployed in the Kuwait Central Blood Bank as well as three distant Blood Banks. This implementation will strengthen biolog-id’s presence in the Middle East region, already installed in Egypt and Saudi Arabia.
About biolog-id
:
Biolog-id develops and implements innovative solutions, that digitally transform routine processes into actionable data supporting better operational and strategic decisions for sensitive therapeutic products.
The information generated by biolog-id solutions is available to Healthcare Professionals at any time, enhancing their processes efficiency, work conditions and ultimately the safety of the therapeutics administered to patients.
Biolog-id’s patented platform is utilized in North America, Europe, Middle East, India, and Asia Pacific. Biolog-id is owned by its founder, managers, and Xerys Invest. Xerys Invest is a French investment company primarily positioned on trending sectors that include healthcare & Life Sciences, renewable energy/GreenTech and new digital technologies.
Company URL: www.biolog-id.com
About Kuwait Central Blood Bank:
The Kuwait Central Blood Bank’s (KCBB) mission is meeting the country’s needs of the patients for safe, high quality and provision of all transfusion services under the supervision of the government. Provision of educational materials and introduction of awareness of the importance of the blood donation to the public.
KCBB URL: www.kuwaitcentralbloodbank.wordpress.com
About Advanced Technology Company:
ATC is a medical equipment supplier to the Kuwait healthcare sector since 1981. Over time, the Company has become the leading distributor and marketer of state-of-the-art healthcare and environmental products and services.
ATC URL: www.atc.com.kw
View source version on businesswire.com: https://www.businesswire.com/news/home/20210831005479/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Convenes Global Supply Chain Leaders at Kinexions North America to Advance Agentic AI and Decision Orchestration28.5.2026 13:00:00 CEST | Press release
Annual conference brings customers, partners, and industry leaders together to explore how enterprises are turning decisions into coordinated action Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, is set to host Kinexions North America kicking off next week from June 1-3 at The Cosmopolitan of Las Vegas. The company’s flagship conference will bring together global supply chain, business and technology leaders for three days of product innovation, customer insights, and peer networking as Kinaxis continues to advance its focus on AI-driven decision making across the supply chain industry. This year’s event will spotlight how organizations are applying agentic AI and orchestration, moving beyond insight to execution, and increasingly from decisions to coordinated action. Speakers from global organizations including Merck, Bristol Myers Squibb, Unilever, British American Tobacco, Qualcomm, ExxonMobil, The Hershey Company, Scotts Miracle-Gro, and
Amadeus Redefines Travel Advertising to Help Brands Capture Demand Earlier28.5.2026 13:00:00 CEST | Press release
Developed in collaboration with Accenture, the AI-powered platform helps travel brands make smarter advertising decisions earlier and drive profitable demand through greater control, transparency, efficiency and performance. Amadeus today introduced the Amadeus Travel Advertising Platform at its Advertising Summit in Nice, France. Leveraging Accenture’s agentic framework for campaign execution, the platform outlines a new approach designed to help travel companies make faster, smarter advertising decisions based on where demand is forming — not just where it has already converted. Travel advertising has become increasingly complex, fragmented across channels and often driven by historical performance signals that arrive too late to capture emerging demand. As travelers plan trips across AI chatbots, search, social, metasearch, content platforms and OTAs long before booking, travel brands face rising acquisition costs and growing pressure to prove return on investment. The Amadeus Trave
Compass Pathways Elects Kathleen Tregoning to Board of Directors28.5.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to its Board of Directors at the annual general meeting of shareholders. Ms. Tregoning is expected to serve on the Compensation and Leadership Development Committee and the Nominating and Corporate Governance Committee. She brings extensive experience guiding biopharmaceutical companies through periods of growth and transformation, with expertise spanning corporate strategy, external affairs, public policy and patient access. “With two successful Phase 3 trials meeting the primary endpoint, a transformative clinical profile for COMP360, and a rolling NDA submission and review now underway, Compass is strongly positioned to make our goal of securing an FDA approval a reality. Compass is entering a stage where experience in external engagement, public policy, and patient access matters more
Alzprotect Announces FDA Clearance of IND for AZP2006 (Ezeprogind®) in Progressive Supranuclear Palsy (PSP)28.5.2026 12:28:00 CEST | Press release
IND enables initiation of U.S. clinical development in PSP Alzprotect today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for AZP2006 (Ezeprogind®) for the treatment of Progressive Supranuclear Palsy (PSP). FDA clearance permits the Company to begin clinical development of AZP2006 in the United States. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526387210/en/ “FDA IND clearance is a pivotal step in our PSP program,” said Philippe Verwaerde, PhD, President & Chief science Officer. “We can now expand our clinical efforts in the U.S. to evaluate AZP2006’s potential to address PSP, a severe neurodegenerative disease with no approved disease-modifying therapies.” Dr. Artin Karapet, Chief Medical Officer, commented: “The FDA’s clearance of our IND for AZP2006 is a pivotal milestone, aligning U.S. and European regulatory pathways and enabling th
LMR by IFF Inaugurates New Experimental Field in Grasse28.5.2026 11:00:00 CEST | Press release
Furthering IFF’s leadership in natural ingredients for perfumery. LMR Naturals by IFF—a global leader in natural ingredients for perfumery, cosmetics and flavors—today inaugurated its new experimental field, Domaine des Naturels LMR. The field is dedicated to advancing research in natural ingredients, preserving Grasse’s agricultural heritage and expanding education in naturals. The inauguration, attended by Grasse Mayor Jérôme Viaud, a long-standing supporter of the perfume industry, underscores IFF and LMR’s ongoing commitment to the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527694524/en/ At Domaine des Naturels LMR, R&D experts research new natural species, variety breeding, cultivation methods and production techniques. “This inauguration reflects over two decades of continuous investment in Grasse and in naturals,” said Ana Paula Mendonça, president, Scent, IFF. “With Domaine des Naturels LMR, we are bri
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom